All In Biotech

Drug Trial Radar · NCT01377922

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)

Last checked: Nov 20, 2026Latest source record: Jan 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

38

Actual

Start

Jun 2011

Primary completion

Jul 2016

Study completion Jul 2016

Sponsor

Lead sponsor
Catalyst Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

Conditions

  • Lambert Eaton Myasthenic Syndrome

Interventions

  • Amifampridine PhosphateDrug

    Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.

  • PlaceboDrug

    Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 DaysTime frame: Assessment at Baseline and Day 14
  2. Change in SGI ScoreTime frame: Assessment at Baseline and Day 14

Locations

14 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    Kansas City, Kansas

  • Site not named

    New York, New York

  • Site not named

    Lyon, France

  • Site not named

    Berlin, Germany

  • Site not named

    Munich, Bavaria, Germany

  • Site not named

    Pécs, Hungary

  • Site not named

    Warsaw, Poland

  • Site not named

    Moscow, Russia

  • Site not named

    Belgrade, Serbia

  • Site not named

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.